Characteristics of materials distributed by drug companies Daniel StryerLisa A. Bero Original Articles Pages: 575 - 583
Effect of physician profiling on utilization E. Andrew BalasSuzanne Austin BorenGerald T. Perkoff Original Articles Pages: 584 - 590
AIDS-relatedPneumocystis carinii pneumonia in older patients Sheri A. KeitzLori A. BastianRobert A. Weinstein Original Articles Pages: 591 - 596
Classifying general medicine readmissions E. Z. OddoneM. Weinbergerthe Veterans Affairs Cooperative Studies in Health Services Group on Primary Care and Hospital Readmissions Original Articles Pages: 597 - 607
Assessment of joint review of radiologic studies by a primary care physician and a radiologist Bjoern C. KnollmannAudrey P. CorsonKevin A. Schulman Original Articles Pages: 608 - 612
Predicting progression to AIDS Linda RabeneckPamela M. HartiganNelda P. Wray Brief Report Pages: 622 - 624
How well can the chest radiograph diagnose left ventricular dysfunction? Robert G. BadgettCynthia D. MulrowGilbert Ramírez Clinical Review Pages: 625 - 634
Why do american drug companies spend more than $12 billion a year pushing drugs? Is it education or promotion? Sidney M. Wolfe Editorials Pages: 637 - 639
Why would anyone have expected anything else? Robert TemplePatrick O’Brien Pharmd Editorials Pages: 640 - 641
Drug companies and information about drugs: recommendations for doctors C. Seth LandefeldMary-Margaret Chren Editorials Pages: 642 - 644
